Investigational drug · Phase 2
E7389-LF
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Neoplasms.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "E7389-LF"
First trial start
2019
Sep 5, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "E7389-LF", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Neoplasms
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "E7389-LF" as an intervention, largest first.
- Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruiting
Eisai Co., Ltd.Eisai
NCT03207672 · 140 participants (planned) · Start Aug 18, 2017 · Primary completion Jul 19, 2018
Drug: E7389-LF · For: Solid Tumor
Sites: Kashiwa, Japan; Sapporo, Japan; Nishinomiya, Japan · 12 sites in all
- A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruiting
Eisai Co., Ltd.Eisai
NCT04078295 · 125 participants · Start Sep 5, 2019 · Primary completion Mar 31, 2027
Drug: E7389-LF; Nivolumab · For: Solid Neoplasms
Sites: Nagoya, Japan; Kashiwa, Japan; Matsuya, Japan · 19 sites in all
Eisai LimitedEisai
NCT01945710 · 62 participants · Start Dec 11, 2012 · Primary completion Oct 2015
Drug: Eribulin-LF · For: Solid Tumors
Sites: Sutton, United Kingdom; Glasgow, United Kingdom; London, United Kingdom · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114.
Ishiguro H, Miyoshi Y, Yasojima H, et al. · Breast Cancer Res 2026
- Preclinical Evaluation of Liposomal Eribulin (E7389-LF) in a Panel of Sarcoma Patient-Derived Xenograft Models.
Jinno M, Yagishita S, Ryu S, et al. · Mol Cancer Ther 2026
- Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?
Shaikh AR, Lin D · J Gastrointest Oncol 2024
- Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.
Oshima T, Yamamoto S, Kawakami H, et al. · BJC Rep 2024
- Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Kawazoe A, Yamamoto N, Sugimoto N, et al. · Clin Cancer Res 2024
- Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M, Murakami S, Kawakami H, et al. · Cancer Res Commun 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eisai.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.